Commercialisation agreement for Ocriplasmin
ThromboGenics NV has entered into an agreement with Alcon for the commercialisation of Ocriplasmin in all markets outside the US. As a result of this deal, ThromboGenics will concentrate on commercialising Ocriplasmin in the US where it plans to build its commercial and medical organisation to support the product’s anticipated launch within the next 12 months.
“Under the terms of the agreement with Alcon, ThromboGenics will receive an up-front payment of €75m. The company is also entitled to a further €90m in potential near-term milestone payments. Additional milestones bring the potential total of up-fronts and milestones to €375m,†said a company spokesman. “In addition, ThromboGenics will receive royalties on net sales of Ocriplasmin that are commensurate with a product that has successfully completed Phase III development and that has been filed for regulatory approval,†he said.
Latest Articles
Addressing Postoperative Visual Complications
Managing aberrations after laser refractive surgery requires a multi-layered approach.
3D Printing Helps Transform Ukrainian Eye Care
The country’s ophthalmologists offer valuable experience in treating ocular trauma and prosthesis design.
Winning Essay Says ‘Collective Desire’ Must Drive DEI Implementation
Emerging Microbial Trends That Could Affect Your Practices
A triptych of challenges paints a concerning picture for ophthalmologists across the globe.
Improving Outcomes with Laser-Assisted Surgery
Femtosecond laser offers a multifunctional tool for improving the safety and efficacy of cataract and refractive lens exchange procedures.
Could the Corneal Transplant Pool Increase?
Modifying or discarding major contraindications for keratoplasty could mean more patients have their sight restored.
Matching Premium IOLs to Visual Lifestyles
From monofocal to full-range solutions, each practice needs comprehensive understanding.
Going Dutch on Acanthamoeba Keratitis
A world-first trial suggests a new medication could beat the disease.
Avoiding Intracorneal Ring Segment Complications
Femtosecond lasers are helping improve refractive results with fewer problems.